Indaptus Therapeutics shares are trading higher after the company announced interim data from the first cohort of four patients in the Phase 1 INDP-D101 trial of its lead compound, Decoy20.
Portfolio Pulse from Benzinga Newsdesk
Indaptus Therapeutics announced interim data from the first cohort of four patients in the Phase 1 INDP-D101 trial of its lead compound, Decoy20, causing its shares to trade higher.

November 06, 2023 | 4:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Indaptus Therapeutics' shares are trading higher after positive interim data from the Phase 1 INDP-D101 trial of Decoy20.
The positive interim data from the Phase 1 INDP-D101 trial of Decoy20 is a significant milestone for Indaptus Therapeutics. This positive news is likely to increase investor confidence in the company, leading to an increase in the company's share price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100